SEC Form 4 · accession 0001209191-17-034968
PLUS THERAPEUTICS, INC. · CNSY
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Anthony Gregg Lapointe
Director
Period of report
May 22, 2017
Accepted (ET)
May 24, 2017 · 4:35 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001095981
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Non-Qualified Stock Option (right to buy)F1,F2 | $1.60 | May 22, 2017 | A | 50,000 | A | — | Mar 31, 2027 | Common Stock | 50,000 | 50,000 | D |
Explanation of responses
- F1The option grant was approved by the issuer's board of directors on March 31, 2017, subject to stockholder approval of the amendment and restatement of the issuer's 2014 Equity Incentive Plan (the "Restated Plan") under which the option was granted. The issuer's stockholders approved the Restated Plan on May 22, 2017.
- F2Fifty percent (50%) of the option shares shall vest on March 31, 2018 with the remaining fifty percent (50%) of the option shares vesting on March 31, 2019.